nodes	percent_of_prediction	percent_of_DWPC	metapath
Indomethacin—migraine—Prednisone—systemic scleroderma	0.194	0.508	CpDpCtD
Indomethacin—osteoarthritis—Prednisone—systemic scleroderma	0.188	0.492	CpDpCtD
Indomethacin—UGT1A9—Mycophenolic acid—systemic scleroderma	0.0434	0.099	CbGbCtD
Indomethacin—UGT2B7—Mycophenolic acid—systemic scleroderma	0.0411	0.0937	CbGbCtD
Indomethacin—CES1—Mycophenolate mofetil—systemic scleroderma	0.04	0.0912	CbGbCtD
Indomethacin—ABCC11—Methotrexate—systemic scleroderma	0.0386	0.0881	CbGbCtD
Indomethacin—UGT1A1—Mycophenolic acid—systemic scleroderma	0.0355	0.081	CbGbCtD
Indomethacin—UGT1A9—Mycophenolate mofetil—systemic scleroderma	0.0243	0.0553	CbGbCtD
Indomethacin—UGT2B7—Mycophenolate mofetil—systemic scleroderma	0.023	0.0524	CbGbCtD
Indomethacin—UGT1A1—Mycophenolate mofetil—systemic scleroderma	0.0198	0.0453	CbGbCtD
Indomethacin—SLCO1B1—Mycophenolate mofetil—systemic scleroderma	0.0137	0.0313	CbGbCtD
Indomethacin—ABCC2—Mycophenolate mofetil—systemic scleroderma	0.0121	0.0275	CbGbCtD
Indomethacin—SLCO1A2—Prednisone—systemic scleroderma	0.0116	0.0266	CbGbCtD
Indomethacin—SLC22A6—Captopril—systemic scleroderma	0.0112	0.0256	CbGbCtD
Indomethacin—ABCC3—Methotrexate—systemic scleroderma	0.0107	0.0243	CbGbCtD
Indomethacin—ALB—Captopril—systemic scleroderma	0.00956	0.0218	CbGbCtD
Indomethacin—SLC22A11—Methotrexate—systemic scleroderma	0.00875	0.0199	CbGbCtD
Indomethacin—SLC22A7—Methotrexate—systemic scleroderma	0.00833	0.019	CbGbCtD
Indomethacin—ABCC4—Methotrexate—systemic scleroderma	0.00814	0.0186	CbGbCtD
Indomethacin—ALB—Mycophenolate mofetil—systemic scleroderma	0.00752	0.0172	CbGbCtD
Indomethacin—ABCB1—Lisinopril—systemic scleroderma	0.00668	0.0152	CbGbCtD
Indomethacin—CYP2C9—Leflunomide—systemic scleroderma	0.00657	0.015	CbGbCtD
Indomethacin—ABCC1—Methotrexate—systemic scleroderma	0.00654	0.0149	CbGbCtD
Indomethacin—ALB—Prednisone—systemic scleroderma	0.00602	0.0137	CbGbCtD
Indomethacin—SLCO1A2—Methotrexate—systemic scleroderma	0.00584	0.0133	CbGbCtD
Indomethacin—SLCO1B1—Methotrexate—systemic scleroderma	0.00551	0.0126	CbGbCtD
Indomethacin—ABCC6—dermis—systemic scleroderma	0.0051	0.111	CbGeAlD
Indomethacin—SLC22A8—Methotrexate—systemic scleroderma	0.00509	0.0116	CbGbCtD
Indomethacin—ABCB1—Captopril—systemic scleroderma	0.005	0.0114	CbGbCtD
Indomethacin—ABCC2—Methotrexate—systemic scleroderma	0.00484	0.011	CbGbCtD
Indomethacin—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.00394	0.00898	CbGbCtD
Indomethacin—CYP2C19—Prednisone—systemic scleroderma	0.0039	0.00889	CbGbCtD
Indomethacin—CYP2C9—cardial valve—systemic scleroderma	0.00374	0.0812	CbGeAlD
Indomethacin—SLC22A6—Methotrexate—systemic scleroderma	0.00354	0.00808	CbGbCtD
Indomethacin—ABCB1—Prednisone—systemic scleroderma	0.00315	0.00718	CbGbCtD
Indomethacin—ALB—Methotrexate—systemic scleroderma	0.00302	0.00688	CbGbCtD
Indomethacin—PPARG—dermis—systemic scleroderma	0.00265	0.0576	CbGeAlD
Indomethacin—ABCB1—Methotrexate—systemic scleroderma	0.00158	0.0036	CbGbCtD
Indomethacin—PPARA—blood vessel—systemic scleroderma	0.00136	0.0295	CbGeAlD
Indomethacin—PTGDR2—tendon—systemic scleroderma	0.00134	0.0292	CbGeAlD
Indomethacin—PTGS2—skeletal joint—systemic scleroderma	0.00117	0.0254	CbGeAlD
Indomethacin—PPARG—artery—systemic scleroderma	0.000957	0.0208	CbGeAlD
Indomethacin—PTGR2—tendon—systemic scleroderma	0.000891	0.0194	CbGeAlD
Indomethacin—PPARG—endothelium—systemic scleroderma	0.000808	0.0176	CbGeAlD
Indomethacin—PTGR2—lung—systemic scleroderma	0.000782	0.017	CbGeAlD
Indomethacin—PPARG—blood vessel—systemic scleroderma	0.000746	0.0162	CbGeAlD
Indomethacin—PLA2G2A—connective tissue—systemic scleroderma	0.000744	0.0162	CbGeAlD
Indomethacin—ABCC6—connective tissue—systemic scleroderma	0.000737	0.016	CbGeAlD
Indomethacin—GLO1—smooth muscle tissue—systemic scleroderma	0.000732	0.0159	CbGeAlD
Indomethacin—GLO1—skin of body—systemic scleroderma	0.000723	0.0157	CbGeAlD
Indomethacin—PPARA—connective tissue—systemic scleroderma	0.000695	0.0151	CbGeAlD
Indomethacin—PLA2G2A—smooth muscle tissue—systemic scleroderma	0.000681	0.0148	CbGeAlD
Indomethacin—CXCL8—smooth muscle tissue—systemic scleroderma	0.000674	0.0146	CbGeAlD
Indomethacin—PTGS2—Fluocinonide—Mometasone—systemic scleroderma	0.000668	0.624	CbGdCrCtD
Indomethacin—PPARA—smooth muscle tissue—systemic scleroderma	0.000636	0.0138	CbGeAlD
Indomethacin—PPARA—skin of body—systemic scleroderma	0.000628	0.0136	CbGeAlD
Indomethacin—GLO1—digestive system—systemic scleroderma	0.000578	0.0126	CbGeAlD
Indomethacin—UGT1A9—digestive system—systemic scleroderma	0.000561	0.0122	CbGeAlD
Indomethacin—GLO1—tendon—systemic scleroderma	0.00055	0.012	CbGeAlD
Indomethacin—PLA2G2A—digestive system—systemic scleroderma	0.000538	0.0117	CbGeAlD
Indomethacin—AKR1C3—smooth muscle tissue—systemic scleroderma	0.000528	0.0115	CbGeAlD
Indomethacin—CES1—connective tissue—systemic scleroderma	0.000516	0.0112	CbGeAlD
Indomethacin—PTGS1—artery—systemic scleroderma	0.000512	0.0111	CbGeAlD
Indomethacin—PLA2G2A—tendon—systemic scleroderma	0.000512	0.0111	CbGeAlD
Indomethacin—PPARA—digestive system—systemic scleroderma	0.000502	0.0109	CbGeAlD
Indomethacin—PTGS2—artery—systemic scleroderma	0.000489	0.0106	CbGeAlD
Indomethacin—GLO1—lung—systemic scleroderma	0.000483	0.0105	CbGeAlD
Indomethacin—SLC10A1—digestive system—systemic scleroderma	0.000483	0.0105	CbGeAlD
Indomethacin—UGT2B7—digestive system—systemic scleroderma	0.000452	0.00983	CbGeAlD
Indomethacin—PLA2G2A—lung—systemic scleroderma	0.000449	0.00976	CbGeAlD
Indomethacin—ABCC6—lung—systemic scleroderma	0.000444	0.00966	CbGeAlD
Indomethacin—CXCL8—lung—systemic scleroderma	0.000444	0.00966	CbGeAlD
Indomethacin—SLC22A11—digestive system—systemic scleroderma	0.000441	0.00958	CbGeAlD
Indomethacin—PTGS1—endothelium—systemic scleroderma	0.000432	0.00939	CbGeAlD
Indomethacin—SLC22A7—digestive system—systemic scleroderma	0.00043	0.00935	CbGeAlD
Indomethacin—PPARA—lung—systemic scleroderma	0.000419	0.00911	CbGeAlD
Indomethacin—PTGS2—endothelium—systemic scleroderma	0.000413	0.00898	CbGeAlD
Indomethacin—PTGS2—Fluticasone Propionate—Mometasone—systemic scleroderma	0.000403	0.376	CbGdCrCtD
Indomethacin—PTGS1—blood vessel—systemic scleroderma	0.000399	0.00866	CbGeAlD
Indomethacin—AKR1C3—tendon—systemic scleroderma	0.000397	0.00863	CbGeAlD
Indomethacin—UGT1A1—digestive system—systemic scleroderma	0.000385	0.00836	CbGeAlD
Indomethacin—PPARG—connective tissue—systemic scleroderma	0.000382	0.00831	CbGeAlD
Indomethacin—PTGS2—blood vessel—systemic scleroderma	0.000381	0.00828	CbGeAlD
Indomethacin—CES1—digestive system—systemic scleroderma	0.000373	0.0081	CbGeAlD
Indomethacin—PPARG—smooth muscle tissue—systemic scleroderma	0.00035	0.0076	CbGeAlD
Indomethacin—AKR1C3—lung—systemic scleroderma	0.000348	0.00757	CbGeAlD
Indomethacin—PPARG—skin of body—systemic scleroderma	0.000345	0.0075	CbGeAlD
Indomethacin—SLCO1B1—digestive system—systemic scleroderma	0.00032	0.00696	CbGeAlD
Indomethacin—CES1—lung—systemic scleroderma	0.000311	0.00676	CbGeAlD
Indomethacin—ABCC3—digestive system—systemic scleroderma	0.000304	0.0066	CbGeAlD
Indomethacin—PPARG—digestive system—systemic scleroderma	0.000276	0.006	CbGeAlD
Indomethacin—PPARG—tendon—systemic scleroderma	0.000263	0.00571	CbGeAlD
Indomethacin—SLCO1A2—digestive system—systemic scleroderma	0.000261	0.00566	CbGeAlD
Indomethacin—ABCC3—lung—systemic scleroderma	0.000254	0.00551	CbGeAlD
Indomethacin—ABCC4—digestive system—systemic scleroderma	0.000251	0.00545	CbGeAlD
Indomethacin—ABCC2—digestive system—systemic scleroderma	0.000243	0.00527	CbGeAlD
Indomethacin—ABCC4—tendon—systemic scleroderma	0.000239	0.00519	CbGeAlD
Indomethacin—ABCB1—blood vessel—systemic scleroderma	0.000236	0.00512	CbGeAlD
Indomethacin—ABCC2—tendon—systemic scleroderma	0.000231	0.00502	CbGeAlD
Indomethacin—PPARG—lung—systemic scleroderma	0.000231	0.00501	CbGeAlD
Indomethacin—SLCO1A2—lung—systemic scleroderma	0.000218	0.00473	CbGeAlD
Indomethacin—ABCC4—lung—systemic scleroderma	0.000209	0.00455	CbGeAlD
Indomethacin—CYP2C19—digestive system—systemic scleroderma	0.000209	0.00453	CbGeAlD
Indomethacin—PTGS1—connective tissue—systemic scleroderma	0.000204	0.00444	CbGeAlD
Indomethacin—ABCC1—tendon—systemic scleroderma	0.000203	0.00442	CbGeAlD
Indomethacin—PTGS2—connective tissue—systemic scleroderma	0.000195	0.00425	CbGeAlD
Indomethacin—PTGS1—smooth muscle tissue—systemic scleroderma	0.000187	0.00406	CbGeAlD
Indomethacin—PTGS1—skin of body—systemic scleroderma	0.000185	0.00401	CbGeAlD
Indomethacin—PTGS2—smooth muscle tissue—systemic scleroderma	0.000179	0.00388	CbGeAlD
Indomethacin—ABCC1—lung—systemic scleroderma	0.000179	0.00388	CbGeAlD
Indomethacin—PTGS2—skin of body—systemic scleroderma	0.000176	0.00383	CbGeAlD
Indomethacin—CYP2C9—digestive system—systemic scleroderma	0.000162	0.00351	CbGeAlD
Indomethacin—PTGS1—digestive system—systemic scleroderma	0.000148	0.00321	CbGeAlD
Indomethacin—PTGS2—digestive system—systemic scleroderma	0.000141	0.00307	CbGeAlD
Indomethacin—PTGS1—tendon—systemic scleroderma	0.00014	0.00305	CbGeAlD
Indomethacin—PTGS2—tendon—systemic scleroderma	0.000134	0.00292	CbGeAlD
Indomethacin—PTGS1—lung—systemic scleroderma	0.000123	0.00268	CbGeAlD
Indomethacin—PTGS2—lung—systemic scleroderma	0.000118	0.00256	CbGeAlD
Indomethacin—ABCB1—digestive system—systemic scleroderma	8.73e-05	0.0019	CbGeAlD
Indomethacin—Decreased appetite—Leflunomide—systemic scleroderma	8.04e-05	0.000737	CcSEcCtD
Indomethacin—Osteoarthritis—Methotrexate—systemic scleroderma	8.03e-05	0.000736	CcSEcCtD
Indomethacin—Confusional state—Lisinopril—systemic scleroderma	8.01e-05	0.000735	CcSEcCtD
Indomethacin—Gastrointestinal pain—Azathioprine—systemic scleroderma	8.01e-05	0.000734	CcSEcCtD
Indomethacin—Headache—Mometasone—systemic scleroderma	8e-05	0.000734	CcSEcCtD
Indomethacin—Insomnia—Mycophenolic acid—systemic scleroderma	7.98e-05	0.000732	CcSEcCtD
Indomethacin—Fatigue—Leflunomide—systemic scleroderma	7.97e-05	0.000731	CcSEcCtD
Indomethacin—Anaphylactic shock—Lisinopril—systemic scleroderma	7.95e-05	0.000729	CcSEcCtD
Indomethacin—Oedema—Lisinopril—systemic scleroderma	7.95e-05	0.000729	CcSEcCtD
Indomethacin—Pruritus—Captopril—systemic scleroderma	7.94e-05	0.000728	CcSEcCtD
Indomethacin—Paraesthesia—Mycophenolic acid—systemic scleroderma	7.92e-05	0.000726	CcSEcCtD
Indomethacin—Ill-defined disorder—Mycophenolate mofetil—systemic scleroderma	7.92e-05	0.000726	CcSEcCtD
Indomethacin—Constipation—Leflunomide—systemic scleroderma	7.91e-05	0.000725	CcSEcCtD
Indomethacin—Pain—Leflunomide—systemic scleroderma	7.91e-05	0.000725	CcSEcCtD
Indomethacin—Anaemia—Mycophenolate mofetil—systemic scleroderma	7.89e-05	0.000723	CcSEcCtD
Indomethacin—Dyspnoea—Mycophenolic acid—systemic scleroderma	7.87e-05	0.000721	CcSEcCtD
Indomethacin—Somnolence—Mycophenolic acid—systemic scleroderma	7.84e-05	0.000719	CcSEcCtD
Indomethacin—Shock—Lisinopril—systemic scleroderma	7.82e-05	0.000717	CcSEcCtD
Indomethacin—Angioedema—Mycophenolate mofetil—systemic scleroderma	7.8e-05	0.000715	CcSEcCtD
Indomethacin—Thrombocytopenia—Lisinopril—systemic scleroderma	7.78e-05	0.000713	CcSEcCtD
Indomethacin—Dyspepsia—Mycophenolic acid—systemic scleroderma	7.77e-05	0.000712	CcSEcCtD
Indomethacin—Tachycardia—Lisinopril—systemic scleroderma	7.76e-05	0.000711	CcSEcCtD
Indomethacin—Body temperature increased—Azathioprine—systemic scleroderma	7.74e-05	0.00071	CcSEcCtD
Indomethacin—Abdominal pain—Azathioprine—systemic scleroderma	7.74e-05	0.00071	CcSEcCtD
Indomethacin—Malaise—Mycophenolate mofetil—systemic scleroderma	7.69e-05	0.000705	CcSEcCtD
Indomethacin—Hyperhidrosis—Lisinopril—systemic scleroderma	7.68e-05	0.000704	CcSEcCtD
Indomethacin—Diarrhoea—Captopril—systemic scleroderma	7.68e-05	0.000704	CcSEcCtD
Indomethacin—Decreased appetite—Mycophenolic acid—systemic scleroderma	7.67e-05	0.000703	CcSEcCtD
Indomethacin—Vertigo—Mycophenolate mofetil—systemic scleroderma	7.66e-05	0.000703	CcSEcCtD
Indomethacin—Syncope—Mycophenolate mofetil—systemic scleroderma	7.65e-05	0.000702	CcSEcCtD
Indomethacin—Leukopenia—Mycophenolate mofetil—systemic scleroderma	7.64e-05	0.0007	CcSEcCtD
Indomethacin—Feeling abnormal—Leflunomide—systemic scleroderma	7.62e-05	0.000699	CcSEcCtD
Indomethacin—Fatigue—Mycophenolic acid—systemic scleroderma	7.61e-05	0.000697	CcSEcCtD
Indomethacin—Nausea—Mometasone—systemic scleroderma	7.59e-05	0.000696	CcSEcCtD
Indomethacin—Anorexia—Lisinopril—systemic scleroderma	7.57e-05	0.000695	CcSEcCtD
Indomethacin—Gastrointestinal pain—Leflunomide—systemic scleroderma	7.56e-05	0.000693	CcSEcCtD
Indomethacin—Weight increased—Prednisone—systemic scleroderma	7.55e-05	0.000693	CcSEcCtD
Indomethacin—Pain—Mycophenolic acid—systemic scleroderma	7.54e-05	0.000692	CcSEcCtD
Indomethacin—Constipation—Mycophenolic acid—systemic scleroderma	7.54e-05	0.000692	CcSEcCtD
Indomethacin—Palpitations—Mycophenolate mofetil—systemic scleroderma	7.54e-05	0.000691	CcSEcCtD
Indomethacin—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	7.5e-05	0.000688	CcSEcCtD
Indomethacin—Hyperglycaemia—Prednisone—systemic scleroderma	7.49e-05	0.000686	CcSEcCtD
Indomethacin—Hypotension—Lisinopril—systemic scleroderma	7.43e-05	0.000681	CcSEcCtD
Indomethacin—Dizziness—Captopril—systemic scleroderma	7.42e-05	0.00068	CcSEcCtD
Indomethacin—Convulsion—Mycophenolate mofetil—systemic scleroderma	7.39e-05	0.000678	CcSEcCtD
Indomethacin—Depression—Prednisone—systemic scleroderma	7.38e-05	0.000677	CcSEcCtD
Indomethacin—Hypertension—Mycophenolate mofetil—systemic scleroderma	7.37e-05	0.000675	CcSEcCtD
Indomethacin—Urticaria—Leflunomide—systemic scleroderma	7.35e-05	0.000674	CcSEcCtD
Indomethacin—Abdominal pain—Leflunomide—systemic scleroderma	7.31e-05	0.00067	CcSEcCtD
Indomethacin—Body temperature increased—Leflunomide—systemic scleroderma	7.31e-05	0.00067	CcSEcCtD
Indomethacin—ABCB1—lung—systemic scleroderma	7.29e-05	0.00158	CbGeAlD
Indomethacin—Feeling abnormal—Mycophenolic acid—systemic scleroderma	7.27e-05	0.000667	CcSEcCtD
Indomethacin—Chest pain—Mycophenolate mofetil—systemic scleroderma	7.26e-05	0.000666	CcSEcCtD
Indomethacin—Neuropathy peripheral—Prednisone—systemic scleroderma	7.25e-05	0.000665	CcSEcCtD
Indomethacin—Anxiety—Mycophenolate mofetil—systemic scleroderma	7.24e-05	0.000664	CcSEcCtD
Indomethacin—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	7.23e-05	0.000663	CcSEcCtD
Indomethacin—Hypersensitivity—Azathioprine—systemic scleroderma	7.22e-05	0.000662	CcSEcCtD
Indomethacin—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	7.21e-05	0.000662	CcSEcCtD
Indomethacin—Insomnia—Lisinopril—systemic scleroderma	7.19e-05	0.000659	CcSEcCtD
Indomethacin—Discomfort—Mycophenolate mofetil—systemic scleroderma	7.18e-05	0.000658	CcSEcCtD
Indomethacin—Paraesthesia—Lisinopril—systemic scleroderma	7.14e-05	0.000654	CcSEcCtD
Indomethacin—Vomiting—Captopril—systemic scleroderma	7.13e-05	0.000654	CcSEcCtD
Indomethacin—Dyspnoea—Lisinopril—systemic scleroderma	7.08e-05	0.00065	CcSEcCtD
Indomethacin—Rash—Captopril—systemic scleroderma	7.08e-05	0.000649	CcSEcCtD
Indomethacin—Dermatitis—Captopril—systemic scleroderma	7.07e-05	0.000648	CcSEcCtD
Indomethacin—Somnolence—Lisinopril—systemic scleroderma	7.06e-05	0.000648	CcSEcCtD
Indomethacin—Headache—Captopril—systemic scleroderma	7.03e-05	0.000645	CcSEcCtD
Indomethacin—Confusional state—Mycophenolate mofetil—systemic scleroderma	7.02e-05	0.000644	CcSEcCtD
Indomethacin—Dyspepsia—Lisinopril—systemic scleroderma	7e-05	0.000641	CcSEcCtD
Indomethacin—Body temperature increased—Mycophenolic acid—systemic scleroderma	6.97e-05	0.00064	CcSEcCtD
Indomethacin—Abdominal pain—Mycophenolic acid—systemic scleroderma	6.97e-05	0.00064	CcSEcCtD
Indomethacin—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	6.96e-05	0.000638	CcSEcCtD
Indomethacin—Oedema—Mycophenolate mofetil—systemic scleroderma	6.96e-05	0.000638	CcSEcCtD
Indomethacin—Asthma—Methotrexate—systemic scleroderma	6.94e-05	0.000636	CcSEcCtD
Indomethacin—Decreased appetite—Lisinopril—systemic scleroderma	6.91e-05	0.000633	CcSEcCtD
Indomethacin—Fatigue—Lisinopril—systemic scleroderma	6.85e-05	0.000628	CcSEcCtD
Indomethacin—Shock—Mycophenolate mofetil—systemic scleroderma	6.85e-05	0.000628	CcSEcCtD
Indomethacin—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	6.82e-05	0.000625	CcSEcCtD
Indomethacin—Hypersensitivity—Leflunomide—systemic scleroderma	6.81e-05	0.000625	CcSEcCtD
Indomethacin—Pain—Lisinopril—systemic scleroderma	6.8e-05	0.000623	CcSEcCtD
Indomethacin—Constipation—Lisinopril—systemic scleroderma	6.8e-05	0.000623	CcSEcCtD
Indomethacin—Tachycardia—Mycophenolate mofetil—systemic scleroderma	6.8e-05	0.000623	CcSEcCtD
Indomethacin—Bradycardia—Prednisone—systemic scleroderma	6.76e-05	0.00062	CcSEcCtD
Indomethacin—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	6.73e-05	0.000617	CcSEcCtD
Indomethacin—Diarrhoea—Azathioprine—systemic scleroderma	6.7e-05	0.000614	CcSEcCtD
Indomethacin—Haemoglobin—Prednisone—systemic scleroderma	6.68e-05	0.000612	CcSEcCtD
Indomethacin—Nausea—Captopril—systemic scleroderma	6.67e-05	0.000611	CcSEcCtD
Indomethacin—Abdominal discomfort—Methotrexate—systemic scleroderma	6.65e-05	0.00061	CcSEcCtD
Indomethacin—Haemorrhage—Prednisone—systemic scleroderma	6.64e-05	0.000609	CcSEcCtD
Indomethacin—Anorexia—Mycophenolate mofetil—systemic scleroderma	6.64e-05	0.000609	CcSEcCtD
Indomethacin—Asthenia—Leflunomide—systemic scleroderma	6.64e-05	0.000608	CcSEcCtD
Indomethacin—Pancytopenia—Methotrexate—systemic scleroderma	6.59e-05	0.000604	CcSEcCtD
Indomethacin—Feeling abnormal—Lisinopril—systemic scleroderma	6.55e-05	0.0006	CcSEcCtD
Indomethacin—Pruritus—Leflunomide—systemic scleroderma	6.54e-05	0.0006	CcSEcCtD
Indomethacin—Hypotension—Mycophenolate mofetil—systemic scleroderma	6.51e-05	0.000597	CcSEcCtD
Indomethacin—Gastrointestinal pain—Lisinopril—systemic scleroderma	6.5e-05	0.000596	CcSEcCtD
Indomethacin—Dizziness—Azathioprine—systemic scleroderma	6.48e-05	0.000594	CcSEcCtD
Indomethacin—Asthenia—Mycophenolic acid—systemic scleroderma	6.33e-05	0.00058	CcSEcCtD
Indomethacin—Diarrhoea—Leflunomide—systemic scleroderma	6.33e-05	0.00058	CcSEcCtD
Indomethacin—Urticaria—Lisinopril—systemic scleroderma	6.31e-05	0.000579	CcSEcCtD
Indomethacin—Insomnia—Mycophenolate mofetil—systemic scleroderma	6.3e-05	0.000577	CcSEcCtD
Indomethacin—Abdominal pain—Lisinopril—systemic scleroderma	6.28e-05	0.000576	CcSEcCtD
Indomethacin—Body temperature increased—Lisinopril—systemic scleroderma	6.28e-05	0.000576	CcSEcCtD
Indomethacin—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL1B—systemic scleroderma	6.25e-05	0.00273	CbGpPWpGaD
Indomethacin—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	6.25e-05	0.000573	CcSEcCtD
Indomethacin—Pruritus—Mycophenolic acid—systemic scleroderma	6.24e-05	0.000572	CcSEcCtD
Indomethacin—CXCL8—Corticotropin-releasing hormone—NOS3—systemic scleroderma	6.24e-05	0.00272	CbGpPWpGaD
Indomethacin—CXCL8—AP-1 transcription factor network—MMP9—systemic scleroderma	6.23e-05	0.00272	CbGpPWpGaD
Indomethacin—Vomiting—Azathioprine—systemic scleroderma	6.23e-05	0.000571	CcSEcCtD
Indomethacin—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	6.21e-05	0.000569	CcSEcCtD
Indomethacin—Somnolence—Mycophenolate mofetil—systemic scleroderma	6.19e-05	0.000568	CcSEcCtD
Indomethacin—Drowsiness—Methotrexate—systemic scleroderma	6.18e-05	0.000567	CcSEcCtD
Indomethacin—Rash—Azathioprine—systemic scleroderma	6.17e-05	0.000566	CcSEcCtD
Indomethacin—Dermatitis—Azathioprine—systemic scleroderma	6.17e-05	0.000566	CcSEcCtD
Indomethacin—Depression—Methotrexate—systemic scleroderma	6.17e-05	0.000565	CcSEcCtD
Indomethacin—Flushing—Prednisone—systemic scleroderma	6.17e-05	0.000565	CcSEcCtD
Indomethacin—Headache—Azathioprine—systemic scleroderma	6.13e-05	0.000563	CcSEcCtD
Indomethacin—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	6.13e-05	0.000562	CcSEcCtD
Indomethacin—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	6.13e-05	0.000562	CcSEcCtD
Indomethacin—Dizziness—Leflunomide—systemic scleroderma	6.12e-05	0.000561	CcSEcCtD
Indomethacin—Renal failure—Methotrexate—systemic scleroderma	6.08e-05	0.000557	CcSEcCtD
Indomethacin—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	6.05e-05	0.000555	CcSEcCtD
Indomethacin—Diarrhoea—Mycophenolic acid—systemic scleroderma	6.04e-05	0.000554	CcSEcCtD
Indomethacin—Stomatitis—Methotrexate—systemic scleroderma	6.03e-05	0.000553	CcSEcCtD
Indomethacin—CXCL8—Allograft Rejection—IL1B—systemic scleroderma	5.99e-05	0.00262	CbGpPWpGaD
Indomethacin—Pain—Mycophenolate mofetil—systemic scleroderma	5.95e-05	0.000546	CcSEcCtD
Indomethacin—Constipation—Mycophenolate mofetil—systemic scleroderma	5.95e-05	0.000546	CcSEcCtD
Indomethacin—Arrhythmia—Prednisone—systemic scleroderma	5.93e-05	0.000544	CcSEcCtD
Indomethacin—Sweating—Methotrexate—systemic scleroderma	5.93e-05	0.000544	CcSEcCtD
Indomethacin—Haematuria—Methotrexate—systemic scleroderma	5.9e-05	0.000541	CcSEcCtD
Indomethacin—Vomiting—Leflunomide—systemic scleroderma	5.88e-05	0.000539	CcSEcCtD
Indomethacin—Alopecia—Prednisone—systemic scleroderma	5.87e-05	0.000538	CcSEcCtD
Indomethacin—PLA2G2A—Spinal Cord Injury—TGFB1—systemic scleroderma	5.86e-05	0.00256	CbGpPWpGaD
Indomethacin—Hypersensitivity—Lisinopril—systemic scleroderma	5.85e-05	0.000537	CcSEcCtD
Indomethacin—Dizziness—Mycophenolic acid—systemic scleroderma	5.83e-05	0.000535	CcSEcCtD
Indomethacin—Epistaxis—Methotrexate—systemic scleroderma	5.83e-05	0.000535	CcSEcCtD
Indomethacin—Rash—Leflunomide—systemic scleroderma	5.83e-05	0.000535	CcSEcCtD
Indomethacin—Dermatitis—Leflunomide—systemic scleroderma	5.83e-05	0.000534	CcSEcCtD
Indomethacin—Nausea—Azathioprine—systemic scleroderma	5.82e-05	0.000533	CcSEcCtD
Indomethacin—CXCL8—Cellular Senescence—IL1A—systemic scleroderma	5.79e-05	0.00253	CbGpPWpGaD
Indomethacin—Headache—Leflunomide—systemic scleroderma	5.79e-05	0.000531	CcSEcCtD
Indomethacin—Erythema—Prednisone—systemic scleroderma	5.78e-05	0.00053	CcSEcCtD
Indomethacin—PLA2G2A—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	5.78e-05	0.00252	CbGpPWpGaD
Indomethacin—Agranulocytosis—Methotrexate—systemic scleroderma	5.77e-05	0.000529	CcSEcCtD
Indomethacin—PTGDR2—Signaling Pathways—SMAD7—systemic scleroderma	5.77e-05	0.00252	CbGpPWpGaD
Indomethacin—PPARA—Developmental Biology—RHOB—systemic scleroderma	5.74e-05	0.00251	CbGpPWpGaD
Indomethacin—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	5.74e-05	0.000526	CcSEcCtD
Indomethacin—CXCL8—Spinal Cord Injury—CCL2—systemic scleroderma	5.73e-05	0.0025	CbGpPWpGaD
Indomethacin—CXCL8—Peptide ligand-binding receptors—EDN1—systemic scleroderma	5.73e-05	0.0025	CbGpPWpGaD
Indomethacin—Asthenia—Lisinopril—systemic scleroderma	5.7e-05	0.000523	CcSEcCtD
Indomethacin—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	5.69e-05	0.000522	CcSEcCtD
Indomethacin—ABCB1—Allograft Rejection—IL13—systemic scleroderma	5.67e-05	0.00248	CbGpPWpGaD
Indomethacin—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—CTGF—systemic scleroderma	5.67e-05	0.00247	CbGpPWpGaD
Indomethacin—PPARG—Generic Transcription Pathway—SMAD7—systemic scleroderma	5.65e-05	0.00247	CbGpPWpGaD
Indomethacin—Pruritus—Lisinopril—systemic scleroderma	5.62e-05	0.000516	CcSEcCtD
Indomethacin—Vomiting—Mycophenolic acid—systemic scleroderma	5.61e-05	0.000514	CcSEcCtD
Indomethacin—CXCL8—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—systemic scleroderma	5.6e-05	0.00244	CbGpPWpGaD
Indomethacin—Haemoglobin—Methotrexate—systemic scleroderma	5.58e-05	0.000512	CcSEcCtD
Indomethacin—AKR1C3—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	5.58e-05	0.00243	CbGpPWpGaD
Indomethacin—Rash—Mycophenolic acid—systemic scleroderma	5.56e-05	0.00051	CcSEcCtD
Indomethacin—Dermatitis—Mycophenolic acid—systemic scleroderma	5.56e-05	0.00051	CcSEcCtD
Indomethacin—Haemorrhage—Methotrexate—systemic scleroderma	5.55e-05	0.000509	CcSEcCtD
Indomethacin—Hepatitis—Methotrexate—systemic scleroderma	5.55e-05	0.000509	CcSEcCtD
Indomethacin—Urticaria—Mycophenolate mofetil—systemic scleroderma	5.53e-05	0.000507	CcSEcCtD
Indomethacin—Headache—Mycophenolic acid—systemic scleroderma	5.53e-05	0.000507	CcSEcCtD
Indomethacin—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	5.5e-05	0.000505	CcSEcCtD
Indomethacin—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	5.5e-05	0.000505	CcSEcCtD
Indomethacin—Nausea—Leflunomide—systemic scleroderma	5.49e-05	0.000504	CcSEcCtD
Indomethacin—Vision blurred—Prednisone—systemic scleroderma	5.45e-05	0.0005	CcSEcCtD
Indomethacin—Diarrhoea—Lisinopril—systemic scleroderma	5.44e-05	0.000499	CcSEcCtD
Indomethacin—Ill-defined disorder—Prednisone—systemic scleroderma	5.37e-05	0.000492	CcSEcCtD
Indomethacin—Anaemia—Prednisone—systemic scleroderma	5.34e-05	0.00049	CcSEcCtD
Indomethacin—Angioedema—Prednisone—systemic scleroderma	5.28e-05	0.000485	CcSEcCtD
Indomethacin—Dizziness—Lisinopril—systemic scleroderma	5.25e-05	0.000482	CcSEcCtD
Indomethacin—Erythema multiforme—Methotrexate—systemic scleroderma	5.25e-05	0.000481	CcSEcCtD
Indomethacin—Nausea—Mycophenolic acid—systemic scleroderma	5.24e-05	0.000481	CcSEcCtD
Indomethacin—PPARA—Transcriptional regulation of white adipocyte differentiation—TGFB1—systemic scleroderma	5.23e-05	0.00228	CbGpPWpGaD
Indomethacin—Malaise—Prednisone—systemic scleroderma	5.21e-05	0.000478	CcSEcCtD
Indomethacin—Vertigo—Prednisone—systemic scleroderma	5.2e-05	0.000476	CcSEcCtD
Indomethacin—Syncope—Prednisone—systemic scleroderma	5.19e-05	0.000476	CcSEcCtD
Indomethacin—Tinnitus—Methotrexate—systemic scleroderma	5.18e-05	0.000475	CcSEcCtD
Indomethacin—PTGDR2—GPCR ligand binding—CCL2—systemic scleroderma	5.14e-05	0.00224	CbGpPWpGaD
Indomethacin—CXCL8—AP-1 transcription factor network—TGFB1—systemic scleroderma	5.13e-05	0.00224	CbGpPWpGaD
Indomethacin—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	5.13e-05	0.00047	CcSEcCtD
Indomethacin—Loss of consciousness—Prednisone—systemic scleroderma	5.08e-05	0.000466	CcSEcCtD
Indomethacin—Vomiting—Lisinopril—systemic scleroderma	5.05e-05	0.000463	CcSEcCtD
Indomethacin—ABCB1—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	5.03e-05	0.0022	CbGpPWpGaD
Indomethacin—Rash—Lisinopril—systemic scleroderma	5.01e-05	0.000459	CcSEcCtD
Indomethacin—Convulsion—Prednisone—systemic scleroderma	5.01e-05	0.000459	CcSEcCtD
Indomethacin—Dermatitis—Lisinopril—systemic scleroderma	5.01e-05	0.000459	CcSEcCtD
Indomethacin—Asthenia—Mycophenolate mofetil—systemic scleroderma	5e-05	0.000458	CcSEcCtD
Indomethacin—Hypertension—Prednisone—systemic scleroderma	4.99e-05	0.000458	CcSEcCtD
Indomethacin—Headache—Lisinopril—systemic scleroderma	4.98e-05	0.000456	CcSEcCtD
Indomethacin—Pruritus—Mycophenolate mofetil—systemic scleroderma	4.93e-05	0.000452	CcSEcCtD
Indomethacin—SLC10A1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	4.92e-05	0.00215	CbGpPWpGaD
Indomethacin—Anxiety—Prednisone—systemic scleroderma	4.91e-05	0.00045	CcSEcCtD
Indomethacin—Alopecia—Methotrexate—systemic scleroderma	4.91e-05	0.00045	CcSEcCtD
Indomethacin—CXCL8—Toll-like Receptor Signaling Pathway—IL1B—systemic scleroderma	4.89e-05	0.00213	CbGpPWpGaD
Indomethacin—Discomfort—Prednisone—systemic scleroderma	4.86e-05	0.000446	CcSEcCtD
Indomethacin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic scleroderma	4.86e-05	0.00212	CbGpPWpGaD
Indomethacin—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic scleroderma	4.86e-05	0.00212	CbGpPWpGaD
Indomethacin—PPARA—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	4.84e-05	0.00211	CbGpPWpGaD
Indomethacin—Erythema—Methotrexate—systemic scleroderma	4.83e-05	0.000443	CcSEcCtD
Indomethacin—CXCL8—Senescence and Autophagy in Cancer—IL1B—systemic scleroderma	4.77e-05	0.00208	CbGpPWpGaD
Indomethacin—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	4.76e-05	0.000437	CcSEcCtD
Indomethacin—Nausea—Lisinopril—systemic scleroderma	4.72e-05	0.000433	CcSEcCtD
Indomethacin—Anaphylactic shock—Prednisone—systemic scleroderma	4.72e-05	0.000433	CcSEcCtD
Indomethacin—Oedema—Prednisone—systemic scleroderma	4.72e-05	0.000433	CcSEcCtD
Indomethacin—CXCL8—Allograft Rejection—TGFB1—systemic scleroderma	4.66e-05	0.00203	CbGpPWpGaD
Indomethacin—Shock—Prednisone—systemic scleroderma	4.64e-05	0.000426	CcSEcCtD
Indomethacin—Tachycardia—Prednisone—systemic scleroderma	4.61e-05	0.000422	CcSEcCtD
Indomethacin—Dizziness—Mycophenolate mofetil—systemic scleroderma	4.6e-05	0.000422	CcSEcCtD
Indomethacin—ABCB1—Allograft Rejection—CTLA4—systemic scleroderma	4.56e-05	0.00199	CbGpPWpGaD
Indomethacin—Hyperhidrosis—Prednisone—systemic scleroderma	4.56e-05	0.000418	CcSEcCtD
Indomethacin—Vision blurred—Methotrexate—systemic scleroderma	4.55e-05	0.000418	CcSEcCtD
Indomethacin—Anorexia—Prednisone—systemic scleroderma	4.5e-05	0.000413	CcSEcCtD
Indomethacin—Ill-defined disorder—Methotrexate—systemic scleroderma	4.48e-05	0.000411	CcSEcCtD
Indomethacin—Anaemia—Methotrexate—systemic scleroderma	4.47e-05	0.00041	CcSEcCtD
Indomethacin—PTGDR2—Signaling Pathways—RHOB—systemic scleroderma	4.46e-05	0.00195	CbGpPWpGaD
Indomethacin—Vomiting—Mycophenolate mofetil—systemic scleroderma	4.43e-05	0.000406	CcSEcCtD
Indomethacin—Rash—Mycophenolate mofetil—systemic scleroderma	4.39e-05	0.000403	CcSEcCtD
Indomethacin—Dermatitis—Mycophenolate mofetil—systemic scleroderma	4.39e-05	0.000402	CcSEcCtD
Indomethacin—CXCL8—Cellular responses to stress—IL1A—systemic scleroderma	4.38e-05	0.00191	CbGpPWpGaD
Indomethacin—Headache—Mycophenolate mofetil—systemic scleroderma	4.36e-05	0.0004	CcSEcCtD
Indomethacin—PPARA—Generic Transcription Pathway—CTGF—systemic scleroderma	4.36e-05	0.0019	CbGpPWpGaD
Indomethacin—Malaise—Methotrexate—systemic scleroderma	4.36e-05	0.0004	CcSEcCtD
Indomethacin—CXCL8—Spinal Cord Injury—IL1B—systemic scleroderma	4.35e-05	0.0019	CbGpPWpGaD
Indomethacin—Vertigo—Methotrexate—systemic scleroderma	4.34e-05	0.000398	CcSEcCtD
Indomethacin—Leukopenia—Methotrexate—systemic scleroderma	4.33e-05	0.000397	CcSEcCtD
Indomethacin—ABCC4—Hemostasis—SELP—systemic scleroderma	4.3e-05	0.00188	CbGpPWpGaD
Indomethacin—Insomnia—Prednisone—systemic scleroderma	4.27e-05	0.000391	CcSEcCtD
Indomethacin—PTGDR2—GPCR downstream signaling—EDN1—systemic scleroderma	4.25e-05	0.00185	CbGpPWpGaD
Indomethacin—Paraesthesia—Prednisone—systemic scleroderma	4.24e-05	0.000389	CcSEcCtD
Indomethacin—AKR1C3—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	4.23e-05	0.00185	CbGpPWpGaD
Indomethacin—PTGDR2—Signaling Pathways—HSPG2—systemic scleroderma	4.21e-05	0.00184	CbGpPWpGaD
Indomethacin—Convulsion—Methotrexate—systemic scleroderma	4.19e-05	0.000384	CcSEcCtD
Indomethacin—Dyspepsia—Prednisone—systemic scleroderma	4.15e-05	0.000381	CcSEcCtD
Indomethacin—ABCB1—HIF-1-alpha transcription factor network—EDN1—systemic scleroderma	4.15e-05	0.00181	CbGpPWpGaD
Indomethacin—Nausea—Mycophenolate mofetil—systemic scleroderma	4.14e-05	0.000379	CcSEcCtD
Indomethacin—CES1—NRF2 pathway—TGFB1—systemic scleroderma	4.13e-05	0.0018	CbGpPWpGaD
Indomethacin—CXCL8—Corticotropin-releasing hormone—TGFB1—systemic scleroderma	4.12e-05	0.0018	CbGpPWpGaD
Indomethacin—PPARG—Developmental Biology—RHOB—systemic scleroderma	4.12e-05	0.0018	CbGpPWpGaD
Indomethacin—Chest pain—Methotrexate—systemic scleroderma	4.11e-05	0.000377	CcSEcCtD
Indomethacin—Decreased appetite—Prednisone—systemic scleroderma	4.1e-05	0.000376	CcSEcCtD
Indomethacin—CXCL8—Spinal Cord Injury—MMP9—systemic scleroderma	4.1e-05	0.00179	CbGpPWpGaD
Indomethacin—Fatigue—Prednisone—systemic scleroderma	4.07e-05	0.000373	CcSEcCtD
Indomethacin—AKR1C3—Disease—SMAD7—systemic scleroderma	4.07e-05	0.00177	CbGpPWpGaD
Indomethacin—Discomfort—Methotrexate—systemic scleroderma	4.07e-05	0.000373	CcSEcCtD
Indomethacin—PTGDR2—Signaling Pathways—CSK—systemic scleroderma	4.06e-05	0.00177	CbGpPWpGaD
Indomethacin—Constipation—Prednisone—systemic scleroderma	4.04e-05	0.00037	CcSEcCtD
Indomethacin—ABCC4—Hemostasis—RHOB—systemic scleroderma	4.01e-05	0.00175	CbGpPWpGaD
Indomethacin—PTGS1—Selenium Micronutrient Network—CCL2—systemic scleroderma	4e-05	0.00175	CbGpPWpGaD
Indomethacin—Confusional state—Methotrexate—systemic scleroderma	3.98e-05	0.000365	CcSEcCtD
Indomethacin—ALB—Vitamin B12 Metabolism—CCL2—systemic scleroderma	3.98e-05	0.00173	CbGpPWpGaD
Indomethacin—ABCC4—Ectoderm Differentiation—CCL2—systemic scleroderma	3.96e-05	0.00173	CbGpPWpGaD
Indomethacin—Anaphylactic shock—Methotrexate—systemic scleroderma	3.94e-05	0.000362	CcSEcCtD
Indomethacin—CXCL8—Peptide ligand-binding receptors—CCL2—systemic scleroderma	3.92e-05	0.00171	CbGpPWpGaD
Indomethacin—Feeling abnormal—Prednisone—systemic scleroderma	3.89e-05	0.000357	CcSEcCtD
Indomethacin—Thrombocytopenia—Methotrexate—systemic scleroderma	3.86e-05	0.000354	CcSEcCtD
Indomethacin—Gastrointestinal pain—Prednisone—systemic scleroderma	3.86e-05	0.000354	CcSEcCtD
Indomethacin—PTGDR2—Signaling by GPCR—EDN1—systemic scleroderma	3.86e-05	0.00168	CbGpPWpGaD
Indomethacin—CXCL8—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	3.84e-05	0.00168	CbGpPWpGaD
Indomethacin—CXCL8—Regulation of toll-like receptor signaling pathway—IL1B—systemic scleroderma	3.81e-05	0.00166	CbGpPWpGaD
Indomethacin—Hyperhidrosis—Methotrexate—systemic scleroderma	3.81e-05	0.00035	CcSEcCtD
Indomethacin—PPARA—Gene Expression—SMAD7—systemic scleroderma	3.8e-05	0.00166	CbGpPWpGaD
Indomethacin—ALB—Platelet activation, signaling and aggregation—SELP—systemic scleroderma	3.78e-05	0.00165	CbGpPWpGaD
Indomethacin—Anorexia—Methotrexate—systemic scleroderma	3.76e-05	0.000345	CcSEcCtD
Indomethacin—ABCB1—Allograft Rejection—HLA-DQB1—systemic scleroderma	3.76e-05	0.00164	CbGpPWpGaD
Indomethacin—Urticaria—Prednisone—systemic scleroderma	3.75e-05	0.000344	CcSEcCtD
Indomethacin—PPARG—Transcriptional regulation of white adipocyte differentiation—TGFB1—systemic scleroderma	3.75e-05	0.00163	CbGpPWpGaD
Indomethacin—Abdominal pain—Prednisone—systemic scleroderma	3.73e-05	0.000342	CcSEcCtD
Indomethacin—Body temperature increased—Prednisone—systemic scleroderma	3.73e-05	0.000342	CcSEcCtD
Indomethacin—AKR1C3—Disease—TGFBI—systemic scleroderma	3.72e-05	0.00162	CbGpPWpGaD
Indomethacin—CXCL8—Senescence and Autophagy in Cancer—TGFB1—systemic scleroderma	3.71e-05	0.00162	CbGpPWpGaD
Indomethacin—Hypotension—Methotrexate—systemic scleroderma	3.69e-05	0.000338	CcSEcCtD
Indomethacin—PPARA—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	3.67e-05	0.0016	CbGpPWpGaD
Indomethacin—ABCC3—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	3.67e-05	0.0016	CbGpPWpGaD
Indomethacin—ABCC4—Hemostasis—CSK—systemic scleroderma	3.66e-05	0.0016	CbGpPWpGaD
Indomethacin—PTGS2—Spinal Cord Injury—IL1A—systemic scleroderma	3.65e-05	0.00159	CbGpPWpGaD
Indomethacin—ABCC4—Platelet degranulation—TGFB1—systemic scleroderma	3.61e-05	0.00158	CbGpPWpGaD
Indomethacin—ABCB1—Allograft Rejection—IL1A—systemic scleroderma	3.57e-05	0.00156	CbGpPWpGaD
Indomethacin—Insomnia—Methotrexate—systemic scleroderma	3.57e-05	0.000327	CcSEcCtD
Indomethacin—ABCB1—Allograft Rejection—CD40LG—systemic scleroderma	3.55e-05	0.00155	CbGpPWpGaD
Indomethacin—Paraesthesia—Methotrexate—systemic scleroderma	3.54e-05	0.000325	CcSEcCtD
Indomethacin—PPARA—Gene Expression—TNFSF13—systemic scleroderma	3.53e-05	0.00154	CbGpPWpGaD
Indomethacin—ALB—Platelet activation, signaling and aggregation—RHOB—systemic scleroderma	3.52e-05	0.00154	CbGpPWpGaD
Indomethacin—Dyspnoea—Methotrexate—systemic scleroderma	3.52e-05	0.000322	CcSEcCtD
Indomethacin—Somnolence—Methotrexate—systemic scleroderma	3.51e-05	0.000322	CcSEcCtD
Indomethacin—CXCL8—SIDS Susceptibility Pathways—IL1B—systemic scleroderma	3.48e-05	0.00152	CbGpPWpGaD
Indomethacin—Hypersensitivity—Prednisone—systemic scleroderma	3.48e-05	0.000319	CcSEcCtD
Indomethacin—Dyspepsia—Methotrexate—systemic scleroderma	3.47e-05	0.000318	CcSEcCtD
Indomethacin—PPARG—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	3.47e-05	0.00151	CbGpPWpGaD
Indomethacin—ABCC4—Response to elevated platelet cytosolic Ca2+—TGFB1—systemic scleroderma	3.44e-05	0.0015	CbGpPWpGaD
Indomethacin—ABCC4—Hemostasis—ITGAM—systemic scleroderma	3.44e-05	0.0015	CbGpPWpGaD
Indomethacin—PPARA—Adipogenesis—TGFB1—systemic scleroderma	3.44e-05	0.0015	CbGpPWpGaD
Indomethacin—Decreased appetite—Methotrexate—systemic scleroderma	3.43e-05	0.000314	CcSEcCtD
Indomethacin—Fatigue—Methotrexate—systemic scleroderma	3.4e-05	0.000312	CcSEcCtD
Indomethacin—PLA2G2A—Metabolism—HSPG2—systemic scleroderma	3.4e-05	0.00148	CbGpPWpGaD
Indomethacin—Asthenia—Prednisone—systemic scleroderma	3.39e-05	0.00031	CcSEcCtD
Indomethacin—CXCL8—Spinal Cord Injury—TGFB1—systemic scleroderma	3.38e-05	0.00147	CbGpPWpGaD
Indomethacin—Pain—Methotrexate—systemic scleroderma	3.37e-05	0.000309	CcSEcCtD
Indomethacin—Pruritus—Prednisone—systemic scleroderma	3.34e-05	0.000306	CcSEcCtD
Indomethacin—Feeling abnormal—Methotrexate—systemic scleroderma	3.25e-05	0.000298	CcSEcCtD
Indomethacin—CXCL8—GPCR downstream signaling—RHOB—systemic scleroderma	3.24e-05	0.00141	CbGpPWpGaD
Indomethacin—ALB—Folate Metabolism—CCL2—systemic scleroderma	3.23e-05	0.00141	CbGpPWpGaD
Indomethacin—Diarrhoea—Prednisone—systemic scleroderma	3.23e-05	0.000296	CcSEcCtD
Indomethacin—Gastrointestinal pain—Methotrexate—systemic scleroderma	3.23e-05	0.000296	CcSEcCtD
Indomethacin—ALB—Platelet activation, signaling and aggregation—CSK—systemic scleroderma	3.21e-05	0.0014	CbGpPWpGaD
Indomethacin—SLCO1A2—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	3.19e-05	0.00139	CbGpPWpGaD
Indomethacin—PTGS2—Selenium Micronutrient Network—CCL2—systemic scleroderma	3.18e-05	0.00139	CbGpPWpGaD
Indomethacin—Urticaria—Methotrexate—systemic scleroderma	3.13e-05	0.000287	CcSEcCtD
Indomethacin—PPARG—Generic Transcription Pathway—CTGF—systemic scleroderma	3.13e-05	0.00136	CbGpPWpGaD
Indomethacin—Dizziness—Prednisone—systemic scleroderma	3.12e-05	0.000286	CcSEcCtD
Indomethacin—Abdominal pain—Methotrexate—systemic scleroderma	3.12e-05	0.000286	CcSEcCtD
Indomethacin—Body temperature increased—Methotrexate—systemic scleroderma	3.12e-05	0.000286	CcSEcCtD
Indomethacin—PTGS1—Selenium Micronutrient Network—IL1B—systemic scleroderma	3.03e-05	0.00132	CbGpPWpGaD
Indomethacin—ALB—Vitamin B12 Metabolism—IL1B—systemic scleroderma	3.02e-05	0.00132	CbGpPWpGaD
Indomethacin—Vomiting—Prednisone—systemic scleroderma	3e-05	0.000275	CcSEcCtD
Indomethacin—UGT1A9—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	2.98e-05	0.0013	CbGpPWpGaD
Indomethacin—Rash—Prednisone—systemic scleroderma	2.98e-05	0.000273	CcSEcCtD
Indomethacin—Dermatitis—Prednisone—systemic scleroderma	2.97e-05	0.000273	CcSEcCtD
Indomethacin—AKR1C3—Disease—HSPG2—systemic scleroderma	2.97e-05	0.00129	CbGpPWpGaD
Indomethacin—Headache—Prednisone—systemic scleroderma	2.96e-05	0.000271	CcSEcCtD
Indomethacin—CXCL8—Signaling by GPCR—RHOB—systemic scleroderma	2.94e-05	0.00128	CbGpPWpGaD
Indomethacin—CXCL8—GPCR ligand binding—EDN1—systemic scleroderma	2.93e-05	0.00128	CbGpPWpGaD
Indomethacin—Hypersensitivity—Methotrexate—systemic scleroderma	2.91e-05	0.000266	CcSEcCtD
Indomethacin—SLC10A1—Metabolism—HSPG2—systemic scleroderma	2.89e-05	0.00126	CbGpPWpGaD
Indomethacin—ABCC1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	2.87e-05	0.00125	CbGpPWpGaD
Indomethacin—AKR1C3—Disease—CSK—systemic scleroderma	2.87e-05	0.00125	CbGpPWpGaD
Indomethacin—AKR1C3—Signaling Pathways—SMAD7—systemic scleroderma	2.85e-05	0.00124	CbGpPWpGaD
Indomethacin—Asthenia—Methotrexate—systemic scleroderma	2.83e-05	0.000259	CcSEcCtD
Indomethacin—Nausea—Prednisone—systemic scleroderma	2.8e-05	0.000257	CcSEcCtD
Indomethacin—Pruritus—Methotrexate—systemic scleroderma	2.79e-05	0.000256	CcSEcCtD
Indomethacin—ABCC3—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	2.78e-05	0.00121	CbGpPWpGaD
Indomethacin—SLCO1B1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	2.73e-05	0.00119	CbGpPWpGaD
Indomethacin—PPARG—Gene Expression—SMAD7—systemic scleroderma	2.72e-05	0.00119	CbGpPWpGaD
Indomethacin—Diarrhoea—Methotrexate—systemic scleroderma	2.7e-05	0.000247	CcSEcCtD
Indomethacin—CXCL8—Metabolism of proteins—ACE—systemic scleroderma	2.7e-05	0.00118	CbGpPWpGaD
Indomethacin—AKR1C3—Disease—CD247—systemic scleroderma	2.69e-05	0.00118	CbGpPWpGaD
Indomethacin—PTGDR2—Signaling by GPCR—CCL2—systemic scleroderma	2.64e-05	0.00115	CbGpPWpGaD
Indomethacin—CXCL8—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	2.63e-05	0.00115	CbGpPWpGaD
Indomethacin—PPARG—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	2.63e-05	0.00115	CbGpPWpGaD
Indomethacin—Dizziness—Methotrexate—systemic scleroderma	2.61e-05	0.000239	CcSEcCtD
Indomethacin—PLA2G2A—Metabolism—CTGF—systemic scleroderma	2.58e-05	0.00112	CbGpPWpGaD
Indomethacin—ALB—Selenium Micronutrient Network—CCL2—systemic scleroderma	2.57e-05	0.00112	CbGpPWpGaD
Indomethacin—PPARG—Gene Expression—TNFSF13—systemic scleroderma	2.53e-05	0.0011	CbGpPWpGaD
Indomethacin—PTGS2—Spinal Cord Injury—CCL2—systemic scleroderma	2.51e-05	0.0011	CbGpPWpGaD
Indomethacin—Vomiting—Methotrexate—systemic scleroderma	2.51e-05	0.00023	CcSEcCtD
Indomethacin—Rash—Methotrexate—systemic scleroderma	2.49e-05	0.000228	CcSEcCtD
Indomethacin—AKR1C3—Metabolism—HSPG2—systemic scleroderma	2.48e-05	0.00108	CbGpPWpGaD
Indomethacin—Dermatitis—Methotrexate—systemic scleroderma	2.48e-05	0.000228	CcSEcCtD
Indomethacin—Headache—Methotrexate—systemic scleroderma	2.47e-05	0.000227	CcSEcCtD
Indomethacin—PPARG—Adipogenesis—TGFB1—systemic scleroderma	2.46e-05	0.00108	CbGpPWpGaD
Indomethacin—ALB—Folate Metabolism—IL1B—systemic scleroderma	2.45e-05	0.00107	CbGpPWpGaD
Indomethacin—PTGS1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	2.43e-05	0.00106	CbGpPWpGaD
Indomethacin—SLCO1A2—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	2.42e-05	0.00106	CbGpPWpGaD
Indomethacin—PTGS2—Selenium Micronutrient Network—IL1B—systemic scleroderma	2.41e-05	0.00105	CbGpPWpGaD
Indomethacin—ABCC3—NRF2 pathway—TGFB1—systemic scleroderma	2.37e-05	0.00104	CbGpPWpGaD
Indomethacin—UGT2B7—NRF2 pathway—TGFB1—systemic scleroderma	2.37e-05	0.00104	CbGpPWpGaD
Indomethacin—Nausea—Methotrexate—systemic scleroderma	2.34e-05	0.000215	CcSEcCtD
Indomethacin—PTGDR2—Signaling Pathways—EDN1—systemic scleroderma	2.28e-05	0.000994	CbGpPWpGaD
Indomethacin—UGT1A9—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	2.26e-05	0.000985	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—SMAD7—systemic scleroderma	2.25e-05	0.00098	CbGpPWpGaD
Indomethacin—ABCC4—NRF2 pathway—TGFB1—systemic scleroderma	2.23e-05	0.000974	CbGpPWpGaD
Indomethacin—AKR1C3—Signaling Pathways—RHOB—systemic scleroderma	2.2e-05	0.000961	CbGpPWpGaD
Indomethacin—SLC10A1—Metabolism—CTGF—systemic scleroderma	2.19e-05	0.000956	CbGpPWpGaD
Indomethacin—ABCC1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	2.18e-05	0.00095	CbGpPWpGaD
Indomethacin—PPARA—Metabolism—HSPG2—systemic scleroderma	2.15e-05	0.00094	CbGpPWpGaD
Indomethacin—PPARA—Gene Expression—CTGF—systemic scleroderma	2.1e-05	0.000916	CbGpPWpGaD
Indomethacin—ABCC1—Disease—SMAD7—systemic scleroderma	2.09e-05	0.000914	CbGpPWpGaD
Indomethacin—AKR1C3—Signaling Pathways—HSPG2—systemic scleroderma	2.08e-05	0.000907	CbGpPWpGaD
Indomethacin—SLCO1B1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	2.07e-05	0.000903	CbGpPWpGaD
Indomethacin—AKR1C3—Signaling Pathways—CSK—systemic scleroderma	2.01e-05	0.000876	CbGpPWpGaD
Indomethacin—CXCL8—GPCR ligand binding—CCL2—systemic scleroderma	2e-05	0.000873	CbGpPWpGaD
Indomethacin—ALB—Selenium Micronutrient Network—IL1B—systemic scleroderma	1.95e-05	0.00085	CbGpPWpGaD
Indomethacin—ALB—Hemostasis—SELP—systemic scleroderma	1.95e-05	0.000849	CbGpPWpGaD
Indomethacin—UGT1A1—NRF2 pathway—TGFB1—systemic scleroderma	1.93e-05	0.000842	CbGpPWpGaD
Indomethacin—UGT1A9—NRF2 pathway—TGFB1—systemic scleroderma	1.93e-05	0.000842	CbGpPWpGaD
Indomethacin—PTGS2—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	1.93e-05	0.000841	CbGpPWpGaD
Indomethacin—ABCC1—Disease—TGFBI—systemic scleroderma	1.92e-05	0.000836	CbGpPWpGaD
Indomethacin—PPARA—Developmental Biology—MMP2—systemic scleroderma	1.91e-05	0.000832	CbGpPWpGaD
Indomethacin—PTGS2—Spinal Cord Injury—IL1B—systemic scleroderma	1.91e-05	0.000831	CbGpPWpGaD
Indomethacin—AKR1C3—Metabolism—CTGF—systemic scleroderma	1.88e-05	0.000822	CbGpPWpGaD
Indomethacin—ABCC2—NRF2 pathway—TGFB1—systemic scleroderma	1.88e-05	0.000821	CbGpPWpGaD
Indomethacin—ABCB1—Allograft Rejection—IL1B—systemic scleroderma	1.86e-05	0.000812	CbGpPWpGaD
Indomethacin—PTGS1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	1.84e-05	0.000803	CbGpPWpGaD
Indomethacin—ALB—Hemostasis—RHOB—systemic scleroderma	1.82e-05	0.000793	CbGpPWpGaD
Indomethacin—PTGS2—Spinal Cord Injury—MMP9—systemic scleroderma	1.8e-05	0.000784	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—RHOB—systemic scleroderma	1.74e-05	0.000758	CbGpPWpGaD
Indomethacin—CXCL8—Metabolism of proteins—MMP1—systemic scleroderma	1.73e-05	0.000755	CbGpPWpGaD
Indomethacin—ABCC4—Hemostasis—MMP1—systemic scleroderma	1.72e-05	0.000752	CbGpPWpGaD
Indomethacin—ALB—Hemostasis—CSK—systemic scleroderma	1.65e-05	0.000722	CbGpPWpGaD
Indomethacin—CXCL8—GPCR downstream signaling—EDN1—systemic scleroderma	1.65e-05	0.000722	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—HSPG2—systemic scleroderma	1.64e-05	0.000715	CbGpPWpGaD
Indomethacin—ALB—Platelet degranulation—TGFB1—systemic scleroderma	1.63e-05	0.000713	CbGpPWpGaD
Indomethacin—UGT2B7—Metabolism—HSPG2—systemic scleroderma	1.63e-05	0.000712	CbGpPWpGaD
Indomethacin—PPARA—Metabolism—CTGF—systemic scleroderma	1.63e-05	0.000712	CbGpPWpGaD
Indomethacin—ABCC3—Metabolism—HSPG2—systemic scleroderma	1.63e-05	0.000712	CbGpPWpGaD
Indomethacin—ABCC4—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	1.6e-05	0.000699	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—CSK—systemic scleroderma	1.58e-05	0.000691	CbGpPWpGaD
Indomethacin—ALB—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	1.56e-05	0.000681	CbGpPWpGaD
Indomethacin—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—systemic scleroderma	1.56e-05	0.000679	CbGpPWpGaD
Indomethacin—PTGDR2—Signaling Pathways—CCL2—systemic scleroderma	1.56e-05	0.000679	CbGpPWpGaD
Indomethacin—ALB—Hemostasis—ITGAM—systemic scleroderma	1.56e-05	0.000679	CbGpPWpGaD
Indomethacin—PPARG—Metabolism—HSPG2—systemic scleroderma	1.54e-05	0.000674	CbGpPWpGaD
Indomethacin—ABCC1—Disease—HSPG2—systemic scleroderma	1.53e-05	0.000667	CbGpPWpGaD
Indomethacin—PPARG—Gene Expression—CTGF—systemic scleroderma	1.5e-05	0.000657	CbGpPWpGaD
Indomethacin—CXCL8—Signaling by GPCR—EDN1—systemic scleroderma	1.5e-05	0.000655	CbGpPWpGaD
Indomethacin—PTGS2—Spinal Cord Injury—TGFB1—systemic scleroderma	1.48e-05	0.000646	CbGpPWpGaD
Indomethacin—ABCC1—Disease—CSK—systemic scleroderma	1.48e-05	0.000644	CbGpPWpGaD
Indomethacin—PTGS2—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	1.46e-05	0.000638	CbGpPWpGaD
Indomethacin—ABCB1—Allograft Rejection—TGFB1—systemic scleroderma	1.45e-05	0.000631	CbGpPWpGaD
Indomethacin—PPARA—Developmental Biology—MMP9—systemic scleroderma	1.43e-05	0.000626	CbGpPWpGaD
Indomethacin—SLCO1A2—Metabolism—HSPG2—systemic scleroderma	1.42e-05	0.00062	CbGpPWpGaD
Indomethacin—CXCL8—Metabolism of proteins—CCL2—systemic scleroderma	1.41e-05	0.000614	CbGpPWpGaD
Indomethacin—PTGS2—Disease—SMAD7—systemic scleroderma	1.41e-05	0.000613	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	1.4e-05	0.000611	CbGpPWpGaD
Indomethacin—PTGDR2—Signaling Pathways—NOS3—systemic scleroderma	1.39e-05	0.000606	CbGpPWpGaD
Indomethacin—ABCC1—Disease—CD247—systemic scleroderma	1.39e-05	0.000605	CbGpPWpGaD
Indomethacin—PPARG—Developmental Biology—MMP2—systemic scleroderma	1.37e-05	0.000596	CbGpPWpGaD
Indomethacin—CXCL8—Metabolism of proteins—MMP2—systemic scleroderma	1.34e-05	0.000584	CbGpPWpGaD
Indomethacin—UGT1A9—Metabolism—HSPG2—systemic scleroderma	1.33e-05	0.000579	CbGpPWpGaD
Indomethacin—UGT1A1—Metabolism—HSPG2—systemic scleroderma	1.33e-05	0.000579	CbGpPWpGaD
Indomethacin—PTGS2—Disease—TGFBI—systemic scleroderma	1.29e-05	0.000561	CbGpPWpGaD
Indomethacin—ABCC1—Metabolism—HSPG2—systemic scleroderma	1.28e-05	0.000558	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	1.28e-05	0.000557	CbGpPWpGaD
Indomethacin—ABCC4—Hemostasis—NOS3—systemic scleroderma	1.25e-05	0.000545	CbGpPWpGaD
Indomethacin—ABCC3—Metabolism—CTGF—systemic scleroderma	1.24e-05	0.00054	CbGpPWpGaD
Indomethacin—UGT2B7—Metabolism—CTGF—systemic scleroderma	1.24e-05	0.00054	CbGpPWpGaD
Indomethacin—SLCO1B1—Metabolism—HSPG2—systemic scleroderma	1.22e-05	0.000531	CbGpPWpGaD
Indomethacin—ALB—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	1.18e-05	0.000516	CbGpPWpGaD
Indomethacin—PPARA—Developmental Biology—TGFB1—systemic scleroderma	1.18e-05	0.000516	CbGpPWpGaD
Indomethacin—PPARG—Metabolism—CTGF—systemic scleroderma	1.17e-05	0.000511	CbGpPWpGaD
Indomethacin—AKR1C3—Signaling Pathways—EDN1—systemic scleroderma	1.12e-05	0.000491	CbGpPWpGaD
Indomethacin—PLA2G2A—Metabolism—NOS3—systemic scleroderma	1.12e-05	0.000489	CbGpPWpGaD
Indomethacin—PTGDR2—Signaling Pathways—MMP9—systemic scleroderma	1.11e-05	0.000486	CbGpPWpGaD
Indomethacin—PTGS1—Metabolism—HSPG2—systemic scleroderma	1.08e-05	0.000472	CbGpPWpGaD
Indomethacin—SLCO1A2—Metabolism—CTGF—systemic scleroderma	1.08e-05	0.00047	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	1.06e-05	0.000463	CbGpPWpGaD
Indomethacin—PPARG—Developmental Biology—MMP9—systemic scleroderma	1.03e-05	0.000448	CbGpPWpGaD
Indomethacin—CXCL8—Signaling by GPCR—CCL2—systemic scleroderma	1.03e-05	0.000448	CbGpPWpGaD
Indomethacin—PTGS2—Disease—HSPG2—systemic scleroderma	1.03e-05	0.000447	CbGpPWpGaD
Indomethacin—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	1.01e-05	0.000439	CbGpPWpGaD
Indomethacin—UGT1A1—Metabolism—CTGF—systemic scleroderma	1.01e-05	0.000439	CbGpPWpGaD
Indomethacin—UGT1A9—Metabolism—CTGF—systemic scleroderma	1.01e-05	0.000439	CbGpPWpGaD
Indomethacin—PTGS2—Disease—CSK—systemic scleroderma	9.9e-06	0.000432	CbGpPWpGaD
Indomethacin—AKR1C3—Disease—NOS3—systemic scleroderma	9.79e-06	0.000427	CbGpPWpGaD
Indomethacin—ABCC1—Metabolism—CTGF—systemic scleroderma	9.7e-06	0.000423	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	9.68e-06	0.000422	CbGpPWpGaD
Indomethacin—SLC10A1—Metabolism—NOS3—systemic scleroderma	9.53e-06	0.000416	CbGpPWpGaD
Indomethacin—PTGS2—Disease—CD247—systemic scleroderma	9.31e-06	0.000406	CbGpPWpGaD
Indomethacin—SLCO1B1—Metabolism—CTGF—systemic scleroderma	9.21e-06	0.000402	CbGpPWpGaD
Indomethacin—PTGDR2—Signaling Pathways—TGFB1—systemic scleroderma	9.18e-06	0.0004	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—EDN1—systemic scleroderma	8.87e-06	0.000387	CbGpPWpGaD
Indomethacin—PTGS2—Metabolism—HSPG2—systemic scleroderma	8.59e-06	0.000375	CbGpPWpGaD
Indomethacin—PPARG—Developmental Biology—TGFB1—systemic scleroderma	8.47e-06	0.000369	CbGpPWpGaD
Indomethacin—ABCC4—Hemostasis—TGFB1—systemic scleroderma	8.26e-06	0.00036	CbGpPWpGaD
Indomethacin—AKR1C3—Metabolism—NOS3—systemic scleroderma	8.2e-06	0.000358	CbGpPWpGaD
Indomethacin—PTGS1—Metabolism—CTGF—systemic scleroderma	8.2e-06	0.000358	CbGpPWpGaD
Indomethacin—ALB—Hemostasis—MMP1—systemic scleroderma	7.8e-06	0.00034	CbGpPWpGaD
Indomethacin—AKR1C3—Signaling Pathways—CCL2—systemic scleroderma	7.69e-06	0.000336	CbGpPWpGaD
Indomethacin—ALB—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	7.25e-06	0.000316	CbGpPWpGaD
Indomethacin—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	7.14e-06	0.000312	CbGpPWpGaD
Indomethacin—PPARA—Metabolism—NOS3—systemic scleroderma	7.11e-06	0.00031	CbGpPWpGaD
Indomethacin—ALB—Metabolism—HSPG2—systemic scleroderma	6.95e-06	0.000303	CbGpPWpGaD
Indomethacin—AKR1C3—Signaling Pathways—NOS3—systemic scleroderma	6.85e-06	0.000299	CbGpPWpGaD
Indomethacin—PTGS2—Metabolism—CTGF—systemic scleroderma	6.51e-06	0.000284	CbGpPWpGaD
Indomethacin—AKR1C3—Disease—TGFB1—systemic scleroderma	6.47e-06	0.000282	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism—HSPG2—systemic scleroderma	6.24e-06	0.000272	CbGpPWpGaD
Indomethacin—ABCB1—Metabolism—HSPG2—systemic scleroderma	6.09e-06	0.000266	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—CCL2—systemic scleroderma	6.07e-06	0.000265	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—HSPG2—systemic scleroderma	5.69e-06	0.000248	CbGpPWpGaD
Indomethacin—ALB—Hemostasis—NOS3—systemic scleroderma	5.65e-06	0.000247	CbGpPWpGaD
Indomethacin—AKR1C3—Signaling Pathways—MMP9—systemic scleroderma	5.5e-06	0.00024	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—NOS3—systemic scleroderma	5.41e-06	0.000236	CbGpPWpGaD
Indomethacin—ABCC3—Metabolism—NOS3—systemic scleroderma	5.39e-06	0.000235	CbGpPWpGaD
Indomethacin—UGT2B7—Metabolism—NOS3—systemic scleroderma	5.39e-06	0.000235	CbGpPWpGaD
Indomethacin—ALB—Metabolism—CTGF—systemic scleroderma	5.26e-06	0.00023	CbGpPWpGaD
Indomethacin—PPARG—Metabolism—NOS3—systemic scleroderma	5.09e-06	0.000222	CbGpPWpGaD
Indomethacin—ABCC1—Disease—NOS3—systemic scleroderma	5.04e-06	0.00022	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism—CTGF—systemic scleroderma	4.73e-06	0.000206	CbGpPWpGaD
Indomethacin—SLCO1A2—Metabolism—NOS3—systemic scleroderma	4.69e-06	0.000205	CbGpPWpGaD
Indomethacin—ABCB1—Metabolism—CTGF—systemic scleroderma	4.61e-06	0.000201	CbGpPWpGaD
Indomethacin—AKR1C3—Signaling Pathways—TGFB1—systemic scleroderma	4.53e-06	0.000198	CbGpPWpGaD
Indomethacin—UGT1A1—Metabolism—NOS3—systemic scleroderma	4.38e-06	0.000191	CbGpPWpGaD
Indomethacin—UGT1A9—Metabolism—NOS3—systemic scleroderma	4.38e-06	0.000191	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—MMP9—systemic scleroderma	4.34e-06	0.000189	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—CTGF—systemic scleroderma	4.31e-06	0.000188	CbGpPWpGaD
Indomethacin—ABCC1—Metabolism—NOS3—systemic scleroderma	4.22e-06	0.000184	CbGpPWpGaD
Indomethacin—SLCO1B1—Metabolism—NOS3—systemic scleroderma	4.01e-06	0.000175	CbGpPWpGaD
Indomethacin—ALB—Hemostasis—TGFB1—systemic scleroderma	3.74e-06	0.000163	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—TGFB1—systemic scleroderma	3.57e-06	0.000156	CbGpPWpGaD
Indomethacin—PTGS1—Metabolism—NOS3—systemic scleroderma	3.57e-06	0.000156	CbGpPWpGaD
Indomethacin—PTGS2—Disease—NOS3—systemic scleroderma	3.38e-06	0.000148	CbGpPWpGaD
Indomethacin—ABCC1—Disease—TGFB1—systemic scleroderma	3.33e-06	0.000145	CbGpPWpGaD
Indomethacin—PTGS2—Metabolism—NOS3—systemic scleroderma	2.83e-06	0.000124	CbGpPWpGaD
Indomethacin—ALB—Metabolism—NOS3—systemic scleroderma	2.29e-06	0.0001	CbGpPWpGaD
Indomethacin—PTGS2—Disease—TGFB1—systemic scleroderma	2.24e-06	9.76e-05	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism—NOS3—systemic scleroderma	2.06e-06	8.98e-05	CbGpPWpGaD
Indomethacin—ABCB1—Metabolism—NOS3—systemic scleroderma	2.01e-06	8.76e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—NOS3—systemic scleroderma	1.88e-06	8.18e-05	CbGpPWpGaD
